A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy.

Trial Profile

A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Pegargiminase (Primary)
  • Indications Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center.
    • 07 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top